Ovarian Cancer


Gradalis Announces a Novel Combination Study of Vigil® EATC in Women with Advanced Ovarian Cancer (January 11, 2017)

Gradalis, Inc. a clinical stage cellular immunotherapy company, developing Vigil® Engineered Autologous Tumor Cell (EATC) therapy, announced that it has entered into a collaboration agreement with Genentech,... Continue Reading

FDA Approves Avastin® (Bevacizumab) Plus Chemotherapy for Treatment of Advanced Ovarian Cancer (January 4, 2017)

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine... Continue Reading

Lynne Cohen Foundation: What an Incredible Year! (December 22, 2016)

WHAT AN INCREDIBLE YEAR! PREVENTIVE CARE CLINICS Our four Lynne Cohen Preventive Care Clinics feature multidisciplinary and personalized preventive care for over 9,500 women facing increased breast or... Continue Reading

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer (December 20, 2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed,... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy.... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase... Continue Reading

FDA Warns Against Ovarian Cancer Screening Tests (October 6, 2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe,... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (September 15, 2016)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly... Continue Reading

Faces of Hope: Ovarian Cancer Advocates Speak Out (September 8, 2016)

Ovarian cancer survivors share their stories to provide inspiration and en­courage awareness of early detection. For many years ovarian cancer has been referred to as “the silent killer” due to its... Continue Reading

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer (September 6, 2016)

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced... Continue Reading

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment (August 22, 2016)

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line... Continue Reading

T-Cells Can be Directed to Treat a Variety of Ovarian Cancers (August 11, 2016)

With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (July 13, 2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United... Continue Reading

West Los Angeles Premier Cancer Prevention 5K Celebrates 15 Years (July 5, 2016)

The Kickin’ Cancer!® 5K Run / Walk / Stroll is the Lynne Cohen Foundation’s flagship event to end women’s cancers through prevention. As a West Los Angeles favorite since 2001, this event celebrates... Continue Reading

Ask the Lynch Syndrome Expert Q&A Now Available (June 2, 2016)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity to... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS